# Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

> **NCT02722538** · PHASE1 · COMPLETED · sponsor: **Taris Biomedical LLC** · enrollment: 23 (actual)

## Conditions studied

- Urinary Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200

## Key facts

- **NCT ID:** NCT02722538
- **Lead sponsor:** Taris Biomedical LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-31
- **Primary completion:** 2019-05-02
- **Final completion:** 2019-05-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722538, "Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02722538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*